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ABSTRACT: Background. The purpose of this study was to assess
aspiration pneumonia (AsPn) rates and predictors after chemo-
irradiation for head and neck cancer.
Methods. The was a prospective study of 72 patients with stage III to IV
oropharyngeal cancer treated definitively with intensity-modulated
radiotherapy (IMRT) concurrent with weekly carboplatin and paclitaxel. AsPn
was recorded prospectively and dysphagia was evaluated longitudinally
through 2 years posttherapy by observer-rated (Common Toxicity Criteria
version [CTCAE]) scores, patient-reported scores, and videofluoroscopy.
Results. Sixteen patients (20%) developed AsPn. Predictive factors
included T classification (p ¼ .01), aspiration detected on
videofluoroscopy (videofluoroscopy-asp; p ¼ .0007), and patient-
reported dysphagia (p ¼ .02–.0003), but not observer-rated dysphagia
(p ¼ .4). Combining T classification, patient reported dysphagia, and
videofluoroscopy-asp, provided the best predictive model.
Conclusion. AsPn continues to be an under-reported consequence of
chemo-irradiation for head and neck cancer. These data support using
patient-reported dysphagia to identify high-risk patients requiring
videofluoroscopy evaluation for preventive measures. Reducing
videofluoroscopy-asp rates, by reducing swallowing structures radiation
doses and by trials reducing treatment intensity in patients predicted to
do well, are likely to reduce AsPn rates. VC 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Long-term dysphagia is a major sequel of chemo-
irradiation of head and neck cancer according to both
observer-rated1 and patient-reported2 assessments. Swal-
lowing studies in these patients are characterized by
decreased coordination between the various phases of the
swallow process, reduced laryngeal elevation and glottic
closure, and reduced inversion of the epiglottis during the
swallow, all of which promote aspiration.3–5 In addition,
reduced movement of the base of tongue and pooling of
residue in the vallecula and pyriform sinuses promote
aspiration after the swallow.3–5 Loss of laryngeal sensa-
tion may accompany these abnormalities causing "silent
aspiration," in which the cough reflex is absent or is not
effective in expelling the aspirate.4–5
We have previously reported an association between
dysphagia in patients receiving intensive chemo-irradia-
tion for head and neck cancer and aspiration pneumonia
(AsPn).3 Literature review at the time showed only anec-
dotal previous reports, suggesting that AsPn was an
under-reported sequel of chemo-irradiation. Several sub-
sequent reports confirmed this observation, with AsPn
rates of 8% to 20%, including cases of death,6–9 and an
even higher aspiration rate of 38% in patients referred for
an evaluation of dysphagia after therapy.10 However, the
large majority of trials of chemo-irradiation trials for
head and neck cancer in the past decade have not detailed
AsPn as a potential sequel of therapy, and its reporting
continues to be anecdotal. For example, pooled database
of late toxicities in Radiation Therapy Oncology Group
studies of chemo-irradiation detailed very few cases of
infections but not AsPn.1 Thus, although AsPn is the
most common cause of death in patients with dysphagia
because of neurologic disorders,11 its rates and conse-
quences after chemo-irradiation for head and neck cancer
are poorly documented.
The purpose of the current study was to assess the
long-term rate of AsPn and its predictors in a prospective
study of chemotherapy concurrent with intensity-modu-
lated radiotherapy (IMRT) for patients with advanced
oropharyngeal cancer. IMRT planning aimed specifically
at reducing the doses to the swallowing-related anatomic
structures. The clinical results of the study showed on
average mild posttherapy dysphagia.12 The analyses
*Corresponding author: A. Eisbruch, Department of Radiation Oncology, 1500 E.
Medical Center Drive, UH B@C490 SPC 5010, Ann Arbor MI 48109. E-mail:
eisbruch@umich.edu
Contract grant sponsor: National Institutes of Health (NIH) grant PO1 CA59827
and the Newman Family Foundation.
This work was presented in part at the 8th International Conference on Head and
Neck Cancer, Toronto, Canada, July 21–25, 2012.
120 HEAD &NECK—DOI 10.1002/HED JANUARY 2014
presented in this article aimed to assess the risk and the
potential predictors of AsPn, including prospective
measures of aspiration risk detected on modified barium
swallow (videofluoroscopy), clinical factors, and
observer-rated and patient-reported dysphagia, collected
longitudinally in the study. Our main goal was to identify
which patients are at high-risk of AsPn so that preventive
measures can be undertaken.
PATIENTS AND METHODS
From 2003 to 2008, 72 patients with stage III to IV
oropharyngeal cancer participated in a prospective study
approved by the University of Michigan Review Board
and all patients signed an informed consent. All received
weekly chemotherapy with carboplatin (area under the
curve [AUC] ¼ 1) and paclitaxel (30 mg/m2) concurrent
with radiotherapy. IMRT prescribed doses were 70 Gy to
gross tumor/involved nodal metastases, 59 to 63 Gy to
high-risk subclinical disease, and 56 to 59 Gy to low-risk
nodal regions, all in 35 fractions over 7 weeks. Planning
priorities included sparing the parts of the oral cavity,
major salivary glands, pharyngeal constrictors, larynx,
and esophagus, which were outside the targets, in an
effort to reduce dysphagia and xerostomia, as detailed
elsewhere.12
Episodes of AsPn were prospectively recorded as part
of the toxicity recording for the clinical study. Patients
were considered to have AsPn based on clinical symp-
toms with corresponding characteristic radiographic
changes.11
Videofluoroscopy was performed before therapy and at
3, 12, and 24 months posttreatment, according to
previously detailed methods.12 Patients with persistent
lymphadenopathy or positron emission tomography-based
suspected residual lymph node disease posttherapy (n ¼
22) underwent planned neck dissection at 3 months and
additional videofluoroscopy at approximately 4 months.
Videofluoroscopy-based aspiration (videofluoroscopy-asp)
was defined once the bolus passed the level of the vocal
folds and entered the subglottic region. For each video-
fluoroscopy study, the number of aspiration events and
the penetration/aspiration (P/A) score13 were recorded,
with the highest (worst) score of the various boluses used
for each patient’s score at each time point. Silent
aspiration or inefficient clearance were noted when an
aspiration event produced nonproductive or no spontane-
ous cough. Patients demonstrating videofluoroscopy-asp
were instructed in using maneuvers to reduce aspiration
and swallow exercises to improve the safety and effi-
ciency of the swallow.14 Feeding tubes were considered
for symptomatic patients who did not improve following
instructions. No preventive swallowing exercise therapy
was used.
Patients completed 2 validated quality of life (QOL)
instruments at baseline and 1, 3, 6, 12, 18, and 24 months
posttreatment: the Head and Neck QOL (HN-QOL) and
the University of Washington QOL (UW-QOL) question-
naires, detailed elsewhere.12 In this study, we analyzed
the results of the dysphagia-related questions 8 and 9
from the HN-QOL questionnaire ("How much are you
bothered by problems with swallowing liquids," and "how
much are you bothered by problems with swallowing sol-
ids?"), question 6b from the UW-QOL questionnaire
("How well do you swallow?"), and the Eating Domain
Score from HN-QOL (a composite score from 6 questions
about problems chewing, dryness while eating, taste,
swallowing solids, and swallowing liquids). The scaling
of scores for each question was modified to range from 0
to 100, with higher scores corresponding to worse condi-
tion, as detailed elsewhere.12 After scaling, each item
score in the Eating Domain was added and the average
sum, including all the items in the Domain, was trans-
formed linearly to produce the summary Domain score,
with 0 the best and 100 the worst score.
Observer-rated toxicities using the Common Terminol-
ogy Criteria for Adverse Events (CTCAE) version 2 scale
were prospectively recorded at baseline and at each
follow-up (every 2 months) throughout 2 years. CTCAE-
dysphagia scores were used in this analysis (0 ¼ no dyspha-
gia; 1 ¼ mild dysphagia without dietary modifications; 2
¼ moderate dysphagia requiring change in diet; 3 ¼
supplemental enteral feeding required; and 4 ¼ oral feed-
ing is not feasible).
Statistical analysis
Logistic regression models were used to assess the
relation between the covariates (clinical factors, observer-
rated and patient-reported dysphagia scores, and video-
fluoroscopy scores). Models for the longitudinally
measured covariates included multiple observations per
subject corresponding to each time a covariate was
measured with associated binary outcome defined as the
presence/absence of any subsequent development of
AsPn. To account for subject correlation, generalized
estimating equations with a first order autoregressive
correlation structure were used to fit the model.
Separate multivariate models were fit using the clinical
variables, the QOL questionnaire and CTCAEdysphagia
scores, and videofluoroscopy-based variables, by includ-
ing all univariately significant variables. Further multivar-
iate models were then built by combining significant fac-
tors from these multivariate models. Empirical receiver
operating characteristic curves were generated from both
univariate and multivariate models. The associated AUC
values were calculated as an overall summary of the dis-
criminatory ability of the model. Whether a particular
variable added to the predictive ability of a model
containing another variable was assessed using the multi-
variate p value from the model containing both variables.
Leave 1 out, cross-validation was used to obtain realistic
estimates of AUC from the multivariate models. The soft-
ware packages R and SAS (V9.2, Cary, NC) were used
for analysis.
RESULTS
Patient characteristics are listed in Table 1. Seventy-
two patients were accrued; 1 patient who declined contin-
ued participation a few months after therapy was
excluded from analysis. Median follow-up for toxicity
was 49 months (range, 12–97 months). Eighteen patients
(25%) required feeding tubes during therapy, of whom 1
(1.4%) required a feeding tube >6 months posttherapy.
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Sixteen patients developed AsPn with 12 requiring
hospitalization and all recovered after various antibiotic
regimens. The actuarial rate of AsPn was 15% at 24
months and 20% at 36 months, with median time from
start of therapy to AsPn at 18 months (range, 1–72
months; Figure 1). No patient had recurrent pneumonia.
Radiological findings included consolidations/opacities of
bilateral lower lobes,5 right lower lobe,3 left lower lobe,5
posterior segments of left upper lobe (1 patient), and
unavailable radiological findings in 2 patients diagnosed
with AsPn and treated elsewhere. Bacterial diagnosis was
made through bronchoscopy in only 1 patient recovering
from oral flora.
Of the clinical variables tested (Table 2), univariate
analysis (UVA) showed current smoking (p ¼ .04) and T
classification (p ¼ .005) to be significantly associated
with the development of AsPn. T classification remained
significant on multivariate analysis (MVA; 0 of 9, 3 of
28, 6 of 16, and 7 of 18 patients with pneumonia/total
patients with T classifications 1, 2, 3, and 4, respectively;
p ¼ .01).
The longitudinal distributions of the patient-reported
and observer-rated dysphagia scores in this study were
detailed elsewhere.12 The scores of the patient-reported
Eating Domain and the dysphagia-related questions 8 and
9 from HN-QOL and question 6b from UW-QOL were
all statistically significant predictors of AsPn on UVA,
but the observer-rated dysphagia scores were not. Of the
16 episodes of pneumonia, the preceding CTCAEdysphagia
scores were 0 to 1 in 11 cases and 2 to 3 in 5 cases (p ¼
.4; Table 3). Eating Domain Score and UW-QOL
question 6b remained significant on MVA (Table 3).
Details of the longitudinal results of videofluoroscopy
in this study were provided elsewhere.12 All patients had
a posttherapy videofluoroscopy study at a minimum of 2
time points. All had a pretreatment videofluoroscopy
evaluation, with 94%, 92%, and 80% having follow-up
studies at 3, 12, and 24 months, respectively. Twenty-two
patients had planned neck dissection 3 months postther-
apy and all had an additional videofluoroscopy study 4
months posttherapy. Videofluoroscopy-asp was noted in
35 patients at least once. Fifty-seven percent of patients
with videofluoroscopy-asp aspirated at only 1 examina-
tion, whereas the rest aspirated on multiple posttherapy
videofluoroscopies. Of 16 patients with AsPn, 13 showed
evidence of videofluoroscopy-asp before the episode of
AsPn. Posttherapy videofluoroscopy-asp (representing any
aspiration found on videofluoroscopy), videofluoroscopy-
based silent aspiration, high P/A score, and the number
of aspiration events recorded on a single videofluoro-
scopy study, were all statistically significant predictors of
AsPn on UVA (Table 4). Because of the strong associa-
tion between all the videofluoroscopy variables (Spear-
man Correlation  0.8), we used videofluoroscopy-asp in
TABLE 1. Patient characteristics.
Age
Median 54.6 y (range, 40–75 y)
Sex
Male 63 (89%)
Female 8 (11%)
Disease site
Base of tongue 38 (54%)
Tonsil 33 (46%)
T classification
T1 9 (13%)
T2 28 (39%)
T3 16 (23%)
T4 18 (25%)
N classification
N0 5 (7%)
N1 6 (8%)
N2a 8 (11%)
N2b 32 (45%)
N2c 14 (20%)
N3 6 (8%)
AJCC stage
III 8 (11%)
IVA 57 (80%)
IVB 6 (8.5%)
BMI (pretreatment)
<18.50 0
18.50–24.99 12 (17%)
25.00–29.99 27 (38%)
30.00 32 (45%)
Weight loss from pretreatment to 3 mo
<10 lbs 9 (13%)
10–20 lbs 16 (23%)
20–30 lbs 17 (24%)
30–40 lbs 14 (20%)
40–50 lbs 11 (15%)
>50 lbs 4 (5%)
Smoking status*
Current smoker 16 (22%)
Former smoker 29 (41%)
Never smoker 26 (37%)
Follow-up
Median 49 mo (range, 12.2–97.2 mo)
Abbreviations: AJCC, American Joint Committee on Cancer; BMI, body mass index.
* For current and past cigarette smokers, the median number of pack-years smoked was 21
(range, 1–140 pack-years).
FIGURE 1. Kaplan–Meier plot of aspiration pneumonia (AsPn)
events since starting therapy.
HUNTER ET AL.
122 HEAD &NECK—DOI 10.1002/HED JANUARY 2014
further modeling because of its highest AUC (0.73). No
difference was observed in the predictive value of early
posttherapy (3 months) versus late (12 or 24 months) vid-
eofluoroscopy-asp in predicting AsPn (AUC 0.76 vs 0.71,
respectively). In contrast to the posttherapy videofluoro-
scopy-asp, aspiration on pretherapy videofluoroscopy was
not a significant factor in developing AsPn (p ¼ .2).
Combining the clinical, patient-reported, and video-
fluoroscopy factors found significant on MVAs (T classi-
fication, Eating Domain Score, UW-QOL question 6b,
and videofluoroscopy-asp) into a single model improved
the AUC significantly (0.87) compared to either factor
alone (Figure 2). Eating Domain scores had the highest
AUC among the patient-reported outcomes (Table 3),
therefore, they were used in the receiver operating charac-
teristic curves.
DISCUSSION
The 20% actuarial rate of long-term posttreatment
AsPn observed in this study is consistent with the rates
reported in previous series, which specifically aimed to
assess AsPn after chemo-irradiation of head and neck
cancer.6–9 However, major clinical trials continue to
under-report the incidence of AsPn, and almost all the tri-
als detailed in a recent review of chemo-irradiation of
head and neck cancer15 have not captured this informa-
tion at all. We suggest that AsPn should be routinely
included as an item in the reporting of toxicities after
chemo-irradiation for head and neck cancer.
In patients with AsPn, the aspiration episode is gener-
ally not witnessed and the diagnosis is inferred when a
patient at risk has radiographic evidence of an infiltrate in
a characteristic bronchopulmonary segment that depends
on patient position at the time of aspiration: basal seg-
ments of lower lobes in patients aspirating while in an
upright or semirecumbent position, and posterior seg-
ments of the upper lobes and apical segments of the
lower lobes in patients aspirating in the recumbent posi-
tion.11 This radiological variety was observed in the
patients in our series. The usual clinical course is an acute
pneumonic process similar to typical community-acquired
pneumonia, however, without effective treatment there is
a higher incidence of cavitation and lung abscess
formation.11
Rehabilitation of the patient at risk of aspiration is per-
formed by speech-language therapists using techniques
including postural changes in head position during the
swallow, swallowing maneuvers designed to close the
entrance to the airway early in the swallow, and diet
modifications.4,5,14 In typical clinical practice, patients are
referred for swallow evaluation only if they present with
high-grade observer-rated dysphagia.10 However, in the
current study, observer-rated dysphagia did not predict
subsequent AsPn. Rather, patient-reported dysphagia, vid-
eofluoroscopy-asp, and advanced T classification, were
significant predictors of AsPn. These findings suggest
that referral for swallow evaluation that includes video-
fluoroscopy should be considered routine practice, espe-
cially in patients with advanced T classification, and not
TABLE 2. Univariate and multivariate analyses of the correlations of clinical variables and aspiration pneumonia.
Variable
Odds
ratio 95% Confidence interval
Univariate
p value
Univariate
AUC
Multivariate
p value
Age 1.06 0.99 1.14 .0935 0.624
Smoking history 1.94 0.56 6.79 .2992 0.571
Current smoker 3.58 1.08 11.9 .0376 0.629 .1386
Baseline BMI 0.97 0.85 1.10 .605 0.54
Disease site
Base of tongue 1.67 0.53 5.21 .380 0.562
Tumor volume, cc 1.01 1.00 1.01 .0688 0.672
T classification 2.54 1.32 4.87 .0050 0.736 .0123
N classification 1.24 0.77 1.99 .3705 0.614
AJCC stage 0.80 0.23 2.80 .721 0.52
Sex 0.43 0.09 2.01 .281 0.549
Neck dissection 0.704 0.199 2.49 .589 0.536
Abbreviations: AUC, area under the curve; BMI, body mass index; AJCC, American Joint Committee on Cancer.
TABLE 3. Univariate and multivariate analysis of the correlation between observer-rated or patient-reported dysphagia variables and subsequent
aspiration pneumonia.
Variable
Odds
ratio*
95% Confidence
interval
Univariate
p value
Univariate
AUC
Multivariate
p value
Observer-rated dysphagia 1.03 0.96 1.10 .41 0.654
HN-QOL question 8 1.16 1.03 1.30 .012 0.63 .402
HN-QOL question 9 1.06 1.01 1.10 .013 0.662 .072
UW-QOL question 6b 1.02 1.00 1.04 .027 0.665 .021
Eating Domain Score 1.12 1.04 1.21 .0029 0.673 .0003
Abbreviations: AUC, area under the curve; HN-QOL, Head and Neck Quality of Life questionnaire; UW-QOL, University of Washington Quality of Life questionnaire.
* The reported odds ratio for the Eating Domain Score is scaled for a 10% increase in Eating Domain Score.
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restricted to those with overt observer-rated dysphagia. In
addition, routine patient-based symptom grading should
be done in addition to observer-rated grading. Dysphagia
is a subjective symptom, likely to be underestimated by
clinicians.16,17 We have previously found that grade 1 ob-
server-rated dysphagia that persisted through 12 months
posttherapy was associated with patient-reported dyspha-
gia and videofluoroscopy findings similar to those found
in patients with higher-grade observer-rated dysphagia.18
Similarly, the Northwestern University group found that
patient self-perception of dysphagia had moderate correla-
tion with videofluoroscopy findings in patients with head
and neck cancer, supporting its complementary role in
the assessment of swallowing.19
AsPn predictors were analyzed by Purkey et al10 in a
retrospective review of 52 patients who presented with
clinical symptoms of dysphagia after therapy. They found
significant correlation between videofluoroscopy-asp and
current smoking and the development of AsPn. Video-
fluoroscopy-asp was also a significant factor in our study,
which assessed all patients regardless of symptoms, and
current smoking was a significant factor on UVA.
The strength of our study was its prospective and longi-
tudinal design. The multiple observations per patient over
time allowed us to calculate the correlations between the
various observations at each time point and subsequent
AsPn, providing predictive estimates. To our knowledge,
this is the first such study of AsPn in head and neck can-
cer. For example, as 57% of videofluoroscopy-asp
occurred on only 1 videofluoroscopy study, it is likely
that some episodes of videofluoroscopy-asp would have
been missed had we not repeated videofluoroscopies at
several time points in each patient. Limitations of this
study include the need to validate its findings in an inde-
pendent cohort and larger patient numbers.
For the radiation oncologist planning IMRT for head
and neck cancer, prospective and retrospective studies in
recent years have provided data about the anatomic struc-
tures whose damage causes dysphagia and aspiration, and
their dose-effect relationships related to videofluoro-
scopy-asp.20–22 Although the current study has produced
some of these dose-effect data,21 they were not yet avail-
able during the study. Using these data to guide IMRT
planning to further improve the sparing of the swallowing
structures outside the targets, as well as trials assessing
reduced treatment intensity in patients predicted to
do well, may reduce the rates of videofluoroscopy-asp.
Taking into account the significant correlations demon-
strated in the current study, reducing videofluoroscopy-
asp rates is likely to reduce the risk of AsPn.
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